H B Carter

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging
    Stacy Loeb
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions and National Institute on Aging, National Institutes of Health Clinical Research Branch, Baltimore, Maryland, USA
    J Urol 180:1314-7; discussion 1317. 2008
  2. ncbi request reprint PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml
    Junyong Fang
    Gerontology Research Center, National Institute on Aging, Baltimore, Maryland, USA
    Urology 59:889-93; discussion 893-4. 2002
  3. ncbi request reprint Improved biomarkers for prostate cancer: a definite need
    H Ballentine Carter
    J Natl Cancer Inst 96:813-5. 2004
  4. pmc Delayed versus immediate surgical intervention and prostate cancer outcome
    Christopher Warlick
    Department of Urology, Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, Baltimore, MD 21287, USA
    J Natl Cancer Inst 98:355-7. 2006
  5. doi request reprint Change in prostate cancer grade over time in men followed expectantly for stage T1c disease
    Todd B Sheridan
    Department of Pathology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    J Urol 179:901-4; discussion 904-5. 2008
  6. pmc Active surveillance for prostate cancer: an underutilized opportunity for reducing harm
    H Ballentine Carter
    Department of Urology, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287 2101, USA
    J Natl Cancer Inst Monogr 2012:175-83. 2012
  7. doi request reprint Management of low (favourable)-risk prostate cancer
    H Ballentine Carter
    Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    BJU Int 108:1684-95. 2011
  8. pmc Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics
    H Ballentine Carter
    Department of Urology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    Asian J Androl 14:355-60. 2012
  9. pmc Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability
    H Ballentine Carter
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Urology 70:685-90. 2007
  10. ncbi request reprint Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience
    H Ballentine Carter
    Department of Urology, The Johns Hopkins University School of Medicine and The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, UAS
    J Urol 178:2359-64; discussion 2364-5. 2007

Detail Information

Publications76

  1. pmc Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging
    Stacy Loeb
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions and National Institute on Aging, National Institutes of Health Clinical Research Branch, Baltimore, Maryland, USA
    J Urol 180:1314-7; discussion 1317. 2008
    ..Thus, we investigated the relationship between changes in prostate size and prostate specific antigen changes in a large cohort of men without prostate cancer...
  2. ncbi request reprint PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml
    Junyong Fang
    Gerontology Research Center, National Institute on Aging, Baltimore, Maryland, USA
    Urology 59:889-93; discussion 893-4. 2002
    ..To evaluate the use of prostate-specific antigen (PSA) velocity (PSAV) in assessing prostate cancer risk among men with PSA levels less than 4.0 ng/mL...
  3. ncbi request reprint Improved biomarkers for prostate cancer: a definite need
    H Ballentine Carter
    J Natl Cancer Inst 96:813-5. 2004
  4. pmc Delayed versus immediate surgical intervention and prostate cancer outcome
    Christopher Warlick
    Department of Urology, Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, Baltimore, MD 21287, USA
    J Natl Cancer Inst 98:355-7. 2006
    ..030, .013, and .008, respectively; two-sided chi-square test). Thus, delayed prostate cancer surgery for patients with small, lower-grade prostate cancers does not appear to compromise curability...
  5. doi request reprint Change in prostate cancer grade over time in men followed expectantly for stage T1c disease
    Todd B Sheridan
    Department of Pathology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    J Urol 179:901-4; discussion 904-5. 2008
    ..We assessed whether the Gleason grade changes in men followed expectantly with nonpalpable prostate cancer diagnosed on needle biopsy (stage T1c)...
  6. pmc Active surveillance for prostate cancer: an underutilized opportunity for reducing harm
    H Ballentine Carter
    Department of Urology, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287 2101, USA
    J Natl Cancer Inst Monogr 2012:175-83. 2012
    ....
  7. doi request reprint Management of low (favourable)-risk prostate cancer
    H Ballentine Carter
    Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    BJU Int 108:1684-95. 2011
    ..A shared-decision approach for selecting optimal management of favourable-risk disease should account for patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments...
  8. pmc Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics
    H Ballentine Carter
    Department of Urology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    Asian J Androl 14:355-60. 2012
    ..PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy...
  9. pmc Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability
    H Ballentine Carter
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Urology 70:685-90. 2007
    ..To determine whether the number of times the prostate-specific antigen (PSA) velocity (PSAV) exceeds a threshold (PSAV risk count) is predictive of high-risk prostate cancer...
  10. ncbi request reprint Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience
    H Ballentine Carter
    Department of Urology, The Johns Hopkins University School of Medicine and The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, UAS
    J Urol 178:2359-64; discussion 2364-5. 2007
    ..We updated our experience with a strategy of expectant treatment for men with stage T1c prostate cancer and evaluated predictors of disease intervention...
  11. pmc Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability
    H Ballentine Carter
    Department of Urology, Marburg 403, Johns Hopkins School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA
    J Natl Cancer Inst 98:1521-7. 2006
    ..The rate at which serum PSA levels change (PSA velocity) may be an important indicator of the presence of life-threatening disease...
  12. pmc Prostate-specific antigen testing of older men
    H B Carter
    Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    J Natl Cancer Inst 91:1733-7. 1999
    ....
  13. ncbi request reprint Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?
    H Ballentine Carter
    Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Urol 173:2040-3. 2005
    ..We evaluated the relationship between baseline prostate specific antigen (PSA) and subsequent lower urinary tract symptom development during 3 decades in unselected men in the Baltimore Longitudinal Study of Aging...
  14. ncbi request reprint Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging
    J Fang
    National Institute on Aging, Gerontology Research Center, Baltimore, Maryland, USA
    Urology 58:411-6. 2001
    ..Those men with the lowest risk of prostate cancer on the basis of the baseline PSA measurements are unlikely to benefit from frequent PSA surveillance in an effort to detect prostate cancer early...
  15. doi request reprint Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level
    Stacy Loeb
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 182:101-4; discussion 105. 2009
    ..Prostate specific antigen is used for prostate cancer screening but its specificity is limited. Specificity might be increased by considering genotype associated prostate specific antigen levels...
  16. ncbi request reprint Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer
    H B Carter
    Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    JAMA 277:1456-60. 1997
    ..To evaluate prostate-specific antigen (PSA) testing intervals that maintain the detection of curable cancer and reduce unnecessary testing...
  17. ncbi request reprint Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer
    S M Harman
    The Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Clin Endocrinol Metab 85:4258-65. 2000
    ..Our data suggest that IGF-II may inhibit both prostate growth and development of prostate cancer...
  18. pmc PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging
    Stacy Loeb
    Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Eur Urol 54:1073-80. 2008
    ..Less is known about the relative utility of pretreatment PSA doubling time (PSA DT) to predict tumor aggressiveness...
  19. ncbi request reprint Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging
    J Slade Hubbard
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Urology 63:253-8. 2004
    ..To examine the relationship of insulin, glucose, and anthropometry with the subsequent risk of prostate cancer...
  20. ncbi request reprint Expectant management of localized prostate cancer
    Masood A Khan
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Urology 62:793-9. 2003
  21. ncbi request reprint Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate
    H B Carter
    Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    World J Urol 15:359-63. 1997
    ..This information is useful when counseling men regarding management options for non-palpable, PSA detected prostate cancer...
  22. ncbi request reprint Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
    J W Simons
    Johns Hopkins Oncology Center, Brady Urological Institute, and Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 59:5160-8. 1999
    ..No antibodies against prostate-specific antigen were detected. These data suggest that both T-cell and B-cell immune responses to human PCA can be generated by treatment with irradiated, GM-CSF gene-transduced PCA vaccines...
  23. pmc Risk stratification of men choosing surveillance for low risk prostate cancer
    Kenneth S Tseng
    Department of Urology, The Johns Hopkins University School of Medicine and The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    J Urol 183:1779-85. 2010
    ..We sought to predict biopsy progression in men on prostate cancer surveillance...
  24. ncbi request reprint Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
    Masood A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Urol 170:2274-8. 2003
    ..Therefore, we determined whether biomarkers could be used to determine those in whom disease is likely to progress and thus those who require definitive therapy...
  25. ncbi request reprint Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease
    J I Epstein
    Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    J Urol 166:1688-91. 2001
    ..Furthermore, men undergoing watchful waiting can be reassured that there is little evidence that prostate cancer grade worsens during the short term...
  26. ncbi request reprint Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation
    Michael C Haffner
    Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 66:371-6. 2005
    ..To examine the impact of neurovascular bundle preservation on longitudinal health-related quality-of-life (HRQOL) outcomes after anatomic radical retropubic prostatectomy (RP) using a validated questionnaire...
  27. ncbi request reprint Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy
    J Kellogg Parsons
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Cancer Epidemiol Biomarkers Prev 14:2257-60. 2005
    ..We prospectively evaluated serum androgen concentrations and prostate cancer risk...
  28. ncbi request reprint Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy
    Christopher A Warlick
    Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Urol Oncol 24:51-7. 2006
    ..Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in use. Outcomes data are still required to determine the safety of expectant treatment for localized disease...
  29. ncbi request reprint The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate
    Danil V Makarov
    James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Urol 176:2383-5. 2006
    ..We review the history of the discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate...
  30. ncbi request reprint Update on PSA testing
    Mark L Gonzalgo
    Department of Urology, Phipps 560 A, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Natl Compr Canc Netw 5:737-42. 2007
    ..Results from ongoing randomized trials will confirm whether prostate cancer screening is an effective method for reducing deaths from prostate cancer and what approaches will provide the most cost-effective screening strategies...
  31. ncbi request reprint Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy
    Ahmed Magheli
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 178:1277-80; discussion 1280-1. 2007
    ..We investigated biochemical outcomes following radical prostatectomy across subclassifications of clinical stage T1 prostate cancer...
  32. doi request reprint Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program
    Jeffrey J Tosoian
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 183:534-8. 2010
    ..We assessed the relationship between PCA3 and prostate biopsy results in men in a surveillance program...
  33. doi request reprint Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program
    Ashley E Ross
    Departments of Urology and Pathology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 28:2810-6. 2010
    ....
  34. pmc Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent
    Danil V Makarov
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Prostate 68:183-9. 2008
    ..We assessed the use of quantitative clinical and pathologic information to predict which patients would eventually require treatment for prostate cancer (CaP) in an expectant management (EM) cohort...
  35. pmc Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging
    Phillip M Pierorazio
    Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    BJU Int 105:824-9. 2010
    ..Study Type - Prognosis (inception cohort) Level of Evidence 1b..
  36. ncbi request reprint Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy
    Jonathan I Epstein
    Department of Pathology, Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Urology 66:356-60. 2005
    ..To determine whether potential candidates for watchful waiting have undersampling of more substantial cancer...
  37. ncbi request reprint Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer
    Sonja I Berndt
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Nutrition 21:686-90. 2005
    ..We assessed whether higher prediagnostic plasma concentrations of vitamin C were associated with a lower risk of prostate cancer in a well-nourished cohort of men...
  38. ncbi request reprint Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy
    Stephen J Freedland
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Urology 65:1131-6. 2005
    ..To study the impact of obesity on the health-related quality-of-life (HRQOL) outcomes after radical prostatectomy (RP)...
  39. ncbi request reprint Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging
    Elizabeth A Platz
    Department of Epidemiology, Room E6138, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
    Cancer Epidemiol Biomarkers Prev 14:390-6. 2005
    ..We evaluated the association of aspirin and nonaspirin NSAIDs with subsequent prostate cancer in a prospective study. We also assessed whether use of these drugs influences serum prostate-specific antigen (PSA) concentration...
  40. ncbi request reprint Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States)
    Lillian J Hsieh
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    Urology 61:297-301. 2003
    ..To examine the association of total energy intake and macronutrient contributors to energy with prostate cancer risk among men in the Baltimore Longitudinal Study of Aging...
  41. ncbi request reprint Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer
    Mohamad E Allaf
    Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 172:1840-4. 2004
    ..This study evaluates the influence of the anatomical extent of pelvic lymph node dissection performed at radical prostatectomy on lymph node yield, staging accuracy and time to prostate specific antigen progression...
  42. ncbi request reprint Effect of local anesthetics on patient recovery after transrectal biopsy
    C L Wu
    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Urology 57:925-9. 2001
    ..CONCLUSIONS: Injection of lidocaine lateral to the seminal vesicles before prostate biopsy did not diminish biopsy-associated pain...
  43. ncbi request reprint Expectant management of nonpalpable prostate cancer with curative intent: preliminary results
    H Ballentine Carter
    Department of Urology and Pathology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    J Urol 167:1231-4. 2002
    ..We evaluate a strategy of expectant management for men with stage T1c prostate cancer...
  44. doi request reprint A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy
    Adeboye O Osunkoya
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
    Urology 72:638-40. 2008
    ....
  45. ncbi request reprint Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages
    Kevin S Ross
    Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Urology 66:1038-42. 2005
    ..The benefits of prostate cancer screening decline with age because of the long natural history of prostate cancer and competing causes of death among older men...
  46. ncbi request reprint The role of prostate-specific antigen velocity in prostate cancer early detection
    S R Potter
    Department of Urology, The Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    Curr Urol Rep 1:15-9. 2000
    ..This review briefly summarizes the theoretic basis and clinical utility of PSAV in prostate cancer early detection...
  47. ncbi request reprint Plasma selenium level before diagnosis and the risk of prostate cancer development
    J D Brooks
    Department of Urology, Stanford University Medical Center, Stanford, California, USA
    J Urol 166:2034-8. 2001
    ..These results support the hypothesis that supplemental selenium may reduce the risk of prostate cancer. Because plasma selenium decreases with patient age, supplementation may be particularly beneficial to older men...
  48. ncbi request reprint Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging
    Sonja I Berndt
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Urology 60:1118-23. 2002
    ..To investigate the association between prostate cancer and calcium and other nutrients thought to influence the synthesis of 1,25-dihydroxyvitamin D [1,25(OH)2D]...
  49. doi request reprint DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme
    Sumit Isharwal
    The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    BJU Int 105:329-33. 2010
    ..Study Type - Prognosis (case series)Level of Evidence 4...
  50. pmc Prostate specific antigen testing among the elderly--when to stop?
    Edward M Schaeffer
    Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    J Urol 181:1606-14; discussion 1613-4. 2009
    ..We evaluated the relationship between prostate specific antigen and the risk of aggressive prostate cancer developing in men of various ages...
  51. doi request reprint Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging
    Stacy Loeb
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 182:2646-51. 2009
    ..We examined the relationship between body mass index and prostate specific antigen by age in men without prostate cancer in a longitudinal aging study to determine whether prostate specific antigen must be adjusted for body mass index...
  52. pmc Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer
    Anna E Kettermann
    Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    BJU Int 106:1284-90; discussion 1290-2. 2010
    ..e. PSA velocity (PSAV). This longitudinal approach might also be extendible to other biomarkers...
  53. ncbi request reprint Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
    W G Nelson
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 46:S67-72. 2000
    ....
  54. ncbi request reprint Importance of posterolateral needle biopsies in the detection of prostate cancer
    J I Epstein
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Urology 57:1112-6. 2001
    ..Maximum cancer detection results from combining both routine sextant and posterolateral needle biopsies...
  55. ncbi request reprint Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle?
    David J Hernandez
    James Buchanan Brady Urological Institute and The Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 173:446-9. 2005
    ..We determined the frequency of positive surgical margins (PSMs) in patients with extraprostatic extension (EPE) in the region of the neurovascular bundle (NVB) who underwent open radical retropubic prostatectomy by 2 experienced surgeons...
  56. doi request reprint Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging
    Stacy Loeb
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    J Urol 182:1458-62. 2009
    ..Although there is an abundance of literature describing prostatic enlargement in association with benign prostatic hyperplasia, less is known about the phenomenon of prostate atrophy...
  57. doi request reprint Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging
    Stacy Loeb
    James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, and the National Institute on Ageing, National Institutes of Health Clinical Research Branch, Baltimore, MD, USA
    BJU Int 106:28-31. 2010
    ..Aetiology (inception cohort) Level of Evidence 2b...
  58. ncbi request reprint Update on watchful waiting for prostate cancer
    Mohamad E Allaf
    The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Curr Opin Urol 14:171-5. 2004
    ..Given the long natural history of such tumors, watchful waiting may represent an effective management strategy for some men. Recent evidence regarding this strategy and our experience is highlighted...
  59. doi request reprint Active surveillance program for prostate cancer: an update of the Johns Hopkins experience
    Jeffrey J Tosoian
    The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, and Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
    J Clin Oncol 29:2185-90. 2011
    ..We assessed outcomes of men with prostate cancer enrolled in active surveillance...
  60. doi request reprint Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes
    Jared Berkowitz
    Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Urology 71:1064-6. 2008
    ..We present the first known man with the exstrophy-epispadias complex to be diagnosed with prostate cancer...
  61. ncbi request reprint Use of spinal anesthesia does not reduce intraoperative blood loss
    Robert P Wong
    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Urology 70:523-6. 2007
    ..To determine whether the use of spinal anesthesia (versus general anesthesia) will result in lower intraoperative blood loss for radical retropubic prostatectomy...
  62. ncbi request reprint Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis
    Jeffrey M Richman
    Department of Anesthesiology, The Johns Hopkins University, Baltimore, Maryland 21287, USA
    Urology 67:1224-8. 2006
    ..To perform a meta-analysis of available randomized trials investigating the analgesic efficacy of periprostatic block with local anesthetic...
  63. ncbi request reprint Disparities in treatment and outcome for renal cell cancer among older black and white patients
    Sonja I Berndt
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 20892 7240, USA
    J Clin Oncol 25:3589-95. 2007
    ..To elucidate reasons for this inequality, we examined differences in treatment and survival between black and white patients...
  64. pmc Metabolic factors associated with benign prostatic hyperplasia
    J Kellogg Parsons
    Division of Urology, University of California San Diego, 200 West Arbor Drive, San Diego, California 21287, USA
    J Clin Endocrinol Metab 91:2562-8. 2006
    ..Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth...
  65. ncbi request reprint Assessing risk: does this patient have prostate cancer?
    H Ballentine Carter
    J Natl Cancer Inst 98:506-7. 2006
  66. ncbi request reprint Continued undertreatment of older men with localized prostate cancer
    H Ballentine Carter
    Urology 64:189-90; author reply 190. 2004
  67. pmc Prostate cancers in men with low PSA levels--must we find them?
    H Ballentine Carter
    N Engl J Med 350:2292-4. 2004
  68. ncbi request reprint Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging
    H Ballentine Carter
    J Natl Cancer Inst 96:557-8. 2004
  69. ncbi request reprint Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 53:468-77. 2008
    ..Screening for PCa has not yet been shown to lower PCa mortality. Still, opportunistic screening is wide spread in Europe and in most other parts of the world...
  70. ncbi request reprint PSA scores: should we use a lower threshold?
    H Ballentine Carter
    Johns Hopkins Med Lett Health After 50 17:6. 2004
  71. ncbi request reprint Consultation corner. Prostate screening: refining what PSA levels mean
    H Ballentine Carter
    Johns Hopkins Med Lett Health After 50 19:6. 2007
  72. ncbi request reprint Informed consent for prostate-specific antigen screening
    H Ballentine Carter
    Urology 61:13-4. 2003
  73. ncbi request reprint Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy
    Evan T Keller
    Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
    Cancer Res 67:9613-5. 2007
  74. ncbi request reprint Prostate cancer early detection. Clinical practice guidelines in oncology
    Mark H Kawachi
    J Natl Compr Canc Netw 5:714-36. 2007
  75. ncbi request reprint Re: long-term followup after laparoscopic radical nephrectomy
    H Ballentine Carter
    J Urol 168:1110; author reply 1110-1. 2002
  76. pmc Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies
    Andrew W Roddam
    Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, United Kingdom
    Ann Intern Med 149:461-71, W83-8. 2008
    ..Some, but not all, published results have shown an association between circulating blood levels of some insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) and the subsequent risk for prostate cancer...